The biotech world is currently witnessing an explosion of technology breakthroughs. As drug discovery becomes more expensive, industry turns to alternative methods such as AI to improve efficiency; New tools allow us to access not only genomes and cells but also microbiomes, opening doors to novel drugs; Major biotech players resource to next-generation technologies such as blockchain to resolve privacy issues; Industry continues to make progress in regenerative medicine...
Â
In turn, this has unveiled Hemi’s Path-to-A and its Series A companies. Since joining Hemi, our portfolio companies have achieved proof-of-concept, de-risked their technologies, and secured partners. Now, they are ready to meet new partners. Going forward, for these companies, there will only be exponential growth.
Hemi Ventures invests in early stage startups in autonomous vehicles, artificial intelligence applications, robotics, biotech, and other emerging technology sectors.Â
Â
We back industry rebels whose innovations are re-shaping the human experience. We invest in ambitious innovation that reshapes the human experience. Â
Â
'Hemi' means 'half' in Greek. We serve as a complementary half to our founders. In addition to capital, we partner with founders to identify synergies and establish relationships that help them grow.Â